MX2022015457A - Deteccion temprana de carcinoma hepatocelular. - Google Patents
Deteccion temprana de carcinoma hepatocelular.Info
- Publication number
- MX2022015457A MX2022015457A MX2022015457A MX2022015457A MX2022015457A MX 2022015457 A MX2022015457 A MX 2022015457A MX 2022015457 A MX2022015457 A MX 2022015457A MX 2022015457 A MX2022015457 A MX 2022015457A MX 2022015457 A MX2022015457 A MX 2022015457A
- Authority
- MX
- Mexico
- Prior art keywords
- hepatocellular carcinoma
- methods
- need
- subjects
- subject
- Prior art date
Links
- 206010073071 hepatocellular carcinoma Diseases 0.000 title abstract 5
- 231100000844 hepatocellular carcinoma Toxicity 0.000 title abstract 5
- 238000001514 detection method Methods 0.000 title 1
- 238000000034 method Methods 0.000 abstract 3
- 238000003556 assay Methods 0.000 abstract 1
- 239000003181 biological factor Substances 0.000 abstract 1
- 230000035945 sensitivity Effects 0.000 abstract 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57438—Specifically defined cancers of liver, pancreas or kidney
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
- G01N33/6857—Antibody fragments
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Pathology (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Gastroenterology & Hepatology (AREA)
- Organic Chemistry (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
- Debugging And Monitoring (AREA)
Abstract
Se proporcionan métodos, ensayos y kits para detectar carcinoma hepatocelular, así como métodos para estratificar sujetos entre categorías de riesgo más altas y más bajas por tener carcinoma hepatocelular y métodos para tratar y manejar el tratamiento de sujetos que se sospecha o están en riesgo de tener carcinoma hepatocelular; aunque el trabajo anterior ha intentado abordar la necesidad de un indicador temprano altamente sensible de carcinoma hepatocelular mediante la evaluación de uno o más factores biológicos, ninguno se ha acercado al grado de sensibilidad que se requiere para la determinación clínicamente relevante de si un sujeto, especialmente un sujeto no sintomático, tiene esa condición; los inventores de la presente han descubierto que ciertas combinaciones de factores satisfacen esta necesidad al conferir un alto nivel de exactitud que no era alcanzable previamente.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662300142P | 2016-02-26 | 2016-02-26 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022015457A true MX2022015457A (es) | 2023-01-16 |
Family
ID=59685568
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2018010285A MX2018010285A (es) | 2016-02-26 | 2017-02-16 | Deteccion temprana de carcinoma hepatocelular. |
| MX2022015457A MX2022015457A (es) | 2016-02-26 | 2018-08-24 | Deteccion temprana de carcinoma hepatocelular. |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2018010285A MX2018010285A (es) | 2016-02-26 | 2017-02-16 | Deteccion temprana de carcinoma hepatocelular. |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US11408888B2 (es) |
| EP (2) | EP4194003A1 (es) |
| JP (2) | JP7026390B2 (es) |
| CN (2) | CN115754291A (es) |
| AU (2) | AU2017223293B2 (es) |
| CA (1) | CA3013792A1 (es) |
| ES (1) | ES2939841T3 (es) |
| MX (2) | MX2018010285A (es) |
| PH (1) | PH12018501813A1 (es) |
| SG (1) | SG11201806822VA (es) |
| TW (2) | TW202311745A (es) |
| WO (1) | WO2017146971A1 (es) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102336498B1 (ko) * | 2020-04-01 | 2021-12-06 | 가톨릭대학교 산학협력단 | 간세포암 진단용 면역글로불린 a 마커 및 이의 용도 |
| WO2022186318A1 (ja) * | 2021-03-03 | 2022-09-09 | 株式会社先端生命科学研究所 | がん検出方法、がん検査方法、及びこれらに用いるキット |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2006244398C1 (en) * | 2005-05-05 | 2016-01-21 | Drexel University | Diagnosis of liver pathology through assessment of protein glycosylation |
| US20090136960A1 (en) * | 2006-03-24 | 2009-05-28 | The Regents Of The University Of Michigan | Methods and compositions for the identification of cancer markers |
| WO2008021163A2 (en) * | 2006-08-09 | 2008-02-21 | Saint Louis University | Kits and methods for determining risk for primary liver cancer |
| US20150198610A9 (en) | 2009-08-05 | 2015-07-16 | Baruch S. Blumberg Institute | Lectin Assay for Assessing Glycoforms as an Early Marker in Disease |
| CN102175839B (zh) * | 2010-12-23 | 2013-08-14 | 中国人民解放军第二军医大学东方肝胆外科医院 | IgG核心岩藻糖基化水平检测方法及其应用 |
-
2017
- 2017-02-16 CN CN202211220644.2A patent/CN115754291A/zh active Pending
- 2017-02-16 JP JP2018544503A patent/JP7026390B2/ja active Active
- 2017-02-16 WO PCT/US2017/018040 patent/WO2017146971A1/en active Application Filing
- 2017-02-16 ES ES17757011T patent/ES2939841T3/es active Active
- 2017-02-16 MX MX2018010285A patent/MX2018010285A/es unknown
- 2017-02-16 EP EP22211176.7A patent/EP4194003A1/en active Pending
- 2017-02-16 US US16/079,352 patent/US11408888B2/en active Active
- 2017-02-16 AU AU2017223293A patent/AU2017223293B2/en active Active
- 2017-02-16 EP EP17757011.6A patent/EP3419646B1/en active Active
- 2017-02-16 CA CA3013792A patent/CA3013792A1/en active Pending
- 2017-02-16 SG SG11201806822VA patent/SG11201806822VA/en unknown
- 2017-02-16 CN CN201780013280.1A patent/CN108697760B/zh active Active
- 2017-02-23 TW TW111121674A patent/TW202311745A/zh unknown
- 2017-02-23 TW TW106106107A patent/TWI769149B/zh active
-
2018
- 2018-08-24 MX MX2022015457A patent/MX2022015457A/es unknown
- 2018-08-24 PH PH12018501813A patent/PH12018501813A1/en unknown
-
2021
- 2021-12-13 JP JP2021201823A patent/JP2022031914A/ja active Pending
-
2022
- 2022-06-23 US US17/808,420 patent/US20230104136A1/en active Pending
-
2024
- 2024-01-12 AU AU2024200227A patent/AU2024200227A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CA3013792A1 (en) | 2017-08-31 |
| EP3419646A1 (en) | 2019-01-02 |
| CN108697760A (zh) | 2018-10-23 |
| MX2018010285A (es) | 2018-12-19 |
| PH12018501813A1 (en) | 2019-06-17 |
| US20190064171A1 (en) | 2019-02-28 |
| ES2939841T3 (es) | 2023-04-27 |
| EP3419646A4 (en) | 2019-10-23 |
| JP2022031914A (ja) | 2022-02-22 |
| TW201734453A (zh) | 2017-10-01 |
| CN108697760B (zh) | 2023-02-17 |
| TW202311745A (zh) | 2023-03-16 |
| JP7026390B2 (ja) | 2022-02-28 |
| TWI769149B (zh) | 2022-07-01 |
| SG11201806822VA (en) | 2018-09-27 |
| AU2017223293A1 (en) | 2018-08-23 |
| AU2017223293B2 (en) | 2023-10-12 |
| EP4194003A1 (en) | 2023-06-14 |
| US20230104136A1 (en) | 2023-04-06 |
| AU2024200227A1 (en) | 2024-02-01 |
| EP3419646B1 (en) | 2022-12-07 |
| CN115754291A (zh) | 2023-03-07 |
| US11408888B2 (en) | 2022-08-09 |
| WO2017146971A1 (en) | 2017-08-31 |
| JP2019512091A (ja) | 2019-05-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2018008421A (es) | Métodos para tratar cáncer y el uso de biomarcadores como predictor de sensibilidad clínica a terapias. | |
| EA202090277A3 (ru) | Применение размера фрагмента бесклеточной днк для определения вариаций числа копий | |
| MX367046B (es) | Marcadores especificos de via para diagnosticar sindrome del intestino irritable. | |
| RU2013146242A (ru) | Fgfr и его лиганды в качестве биомаркеров рака молочной железы у hr-положительных индивидуумов | |
| WO2015094995A3 (en) | Gene signature biomarkers of tumor response to pd-1 antagonists | |
| PH12017502200A1 (en) | Methods of diagnosing and treating cancer | |
| RU2015125575A (ru) | Композиции и способы для лечения злокачественной опухоли | |
| EA201791578A1 (ru) | Панель биомаркеров для обнаружения рака | |
| MX357550B (es) | Microarn plasmaticos para la deteccion de cancer colorrectal temprano. | |
| ES2570380T3 (es) | Método para determinar la aptitud de inhibidores de EZH2 humano en tratamiento | |
| TR201904386T4 (tr) | Nükleotidleri içeren nükleozomların saptanmasına yönelik yöntem. | |
| EA201891304A1 (ru) | ИНГИБИТОРЫ MAT2A ДЛЯ ЛЕЧЕНИЯ MTAP-null ЗЛОКАЧЕСТВЕННЫХ ОПУХОЛЕЙ | |
| MX352274B (es) | Metodos para mejorar el diagnostico de enfermedad inflamatoria intestinal. | |
| MX2020012548A (es) | Métodos para el tratamiento de mieloma múltiple y uso de biomarcadores para 4-(4-(4-(((2-(2,6-dioxopiperidin-3-il)-1-oxoiso indolin-4-il)oxi)metil)bencil)piperazin-1- il)-3-fluorobenzonitril o. | |
| EA201790696A1 (ru) | Способы и композиции для диагностики и прогнозирования повреждения почек и почечной недостаточности | |
| EA201891571A1 (ru) | Геномное профилирование отдельных циркулирующих опухолевых клеток (ctc) при метастазирующем заболевании для характеризации гетерогенности заболевания | |
| MX2019008260A (es) | Metodos y composiciones para la evaluacion y tratamiento de lesion renal e insuficiencia renal con base en la medicion del ligando 14 de quimiocina de la porcion c-c. | |
| MY193564A (en) | Detection reagent, detection kit and detection method for itga4 gene methylation | |
| PH12018501813A1 (en) | Early detection of hepatocellular carcinoma | |
| NZ722492A (en) | Specific biomarker set for non-invasive diagnosis of liver cancer | |
| EA201691499A1 (ru) | Диагностика с помощью циркулирующих опухолевых клеток биомаркеров, позволяющих предсказывать резистентность по отношению к направленным на андрогеновый рецептор (ar) терапиям | |
| BR112016013976A2 (pt) | método para determinar se um indivíduo é afetado por um câncer, método para discriminar entre câncer colorretal e pancreático dentre indivíduos que resultam ser positivos para o método, método para determinar o estágio de um câncer colorretal em um indivíduo afetado e uso de um kit de rt-pcr quantitativo para performar o método | |
| MX2022005159A (es) | Uso de biomarcadores para predecir la sensibilidad clinica a 2-(4-clorofenil)-n-((2-(2,6-dioxopiperidin-3-il)-1-oxoisoindolin- 5-il)metil)-2,2-difluoroacetamida. | |
| BR112016029562A2 (pt) | métodos para tratar, diagnosticar e prognosticar uma malignidade hematológica | |
| BR112018013381A2 (pt) | anticorpo especificamente ligante a antígenos derivados de miobacteria ou fragmento ligante a antígeno do mesmo |